ClinicalTrials.gg
CompletedNCT03520920Updated Oct 26, 2024Results posted

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

A Phase 2 interventional study of Zanubrutinib and Rituximab in Marginal Zone Lymphoma, Follicular Lymphoma and Diffuse Large B-Cell Lymphoma, sponsored by BeiGene. Completed at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2018, registered Apr 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Lymphoma, B-Cell, Marginal Zone with a site in China — 35 open to participants now, 43 under way, 4 of them phase 3. Lymphoma, B-Cell, Marginal Zone · China.

Enrollment
42nd of 53
41 · median 68
Started
2018
with 1 other
Phase 2
31 of 58
17 open now
Registered
2nd of 58
by date
Lead sponsor
3 of 58
BeiGene

Among the 58 studies in Lymphoma, B-Cell, Marginal Zone with a site in China, this one is the 42nd largest by enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2018, is one of 31 in phase 2, and was the 2nd registered.

Lymphoma, B-Cell, Marginal Zone

875 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 111 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

35 of the 58 studies in Lymphoma, B-Cell, Marginal Zone with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 92 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 77 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Lymphoma, B-Cell, Marginal Zone with a site in China, or all of them as a file.
02

Study summary

This was a multicenter, open-label, phase 2 study to evaluate efficacy, safety, and tolerability of BGB-3111 (zanubrutinib) 160 milligrams (mg) twice daily (BID) in combination with rituximab in Chinese participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (non-GCB [non-germinal center B-cell-like] subtype) and R/R indolent lymphoma (follicular lymphoma [FL] and marginal zone lymphoma [MZL]).

03

Conditions studied

  • Marginal Zone Lymphoma
  • Follicular Lymphoma
  • Diffuse Large B-Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. ≥ Age 18 years at time of signing of .
  2. by computed tomography (CT) or positron emission tomography/CT or magnetic resonance imaging, defined as ≥1 nodal lesion that was >1.5 centimeters (cm) in the longest diameter, or ≥1 extra-nodal lesion (for example, hepatic nodules) that was >1 cm in the longest diameter.
  3. Availability of archival or fresh tumor tissue sample from an evaluable core or excisional .
  4. Participants meet the following criteria:

    1. Cohort 1: R/R non-GCB DLBCL i. confirmed non-GCB DLBCL per Hans criteria with non-transformed disease; additional methodologies for confirming non-GCB DLBCL may have been considered in consultation with the medical monitor. ii. disease (disease progression after most recent therapy for DLBCL occurring more than 6 months after the completion of last therapy) or refractory disease (failure to achieve complete response [CR] or partial response [PR] to therapy for non-GCB DLBCL or disease progression within 6 months after completion of the most recent therapy for non-GCB DLBCL). iii. Must have received at least one standard anthracycline ± rituximab-based treatment (for example, rituximab plus cyclophosphamide, doxorubicin [or epirubicin, hydroxydaunorubicin, or similar], vincristine, and prednisone) or cyclophosphamide, vincristine, and prednisone +/- rituximab for DLBCL.
    2. Cohort 2: R/R FL or R/R MZL i. Histologically confirmed CD20+ FL (Grade 1, 2, or 3a) or MZL. ii. Relapsed disease (disease progression after most recent therapy for FL or MZL occurring more than 6 months after the completion of last therapy) or refractory disease (failure to achieve complete response (CR) or partial response (PR) to most recent therapy for FL or MZL, or disease progression within 6 months after completion of the most recent therapy for FL or MZL).
  5. Laboratory parameters as specified below:

    1. Hematologic: count ≥75 x 10\^9/liter (L) independent of growth factor or transfusion within 7 days of study entry; (ANC) ≥1 x 10\^9/L independent of growth factor within 7 days of study entry, >8 grams/deciliter within 7 days of study entry.
    2. Hepatic: Total ≤ 2x (ULN) unless documented Gilbert's syndrome; /serum glutamic-oxaloacetic transaminase and alanine transaminase/serum glutamic-pyruvic transaminase ≤3x ULN.
    3. Renal: ≥30 milliliters/minute (as estimated by the Cockcroft-Gault equation based on ideal body weight or as measured by nuclear medicine scan or 24-hour urine collection).
    4. and activated partial thromboplastin time ≤1.5x ULN. Participants with anti-phospholipid syndrome, acquired von Willebrand disease, factor inhibitors or on vitamin K antagonist may have been enrolled after discussion with the Medical Monitor.
  6. ≥50%.
  7. ≥6 months.
  8. performance status of 0, 1, or 2.
  9. Female participants of must have practiced highly effective methods of initiated prior to first dose of study drug, for the duration of the study, and for ≥90 days after the last dose of zanubrutinib, or 12 months after the last dose of rituximab, whichever is longer.
  10. Male participants were eligible if vasectomized or if they agreed to the use of barrier contraception in combination with other methods above during the study treatment period and for ≥90 days after the last dose of zanubrutinib.
  11. Able to provide written informed consent and could understand and comply with the requirements of the study.

Key Exclusion Criteria:

  1. Known central nervous system lymphoma or leukemia.
  2. Histological confirmed gastric mucosa-associated lymphoid tissue type MZL.
  3. Uncontrolled hemolytic anemia or idiopathic thrombocytopenia purpura.
  4. cardiovascular disease.
  5. History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention.
  6. History of stroke or intracranial hemorrhage within 6 months before first dose of study drug.
  7. Severe or debilitating pulmonary disease.
  8. reaction to zanubrutinib or rituximab or any of the other ingredients of the study drugs.
  9. Prior Bruton tyrosine kinase inhibitor treatment.
  10. Required ongoing treatment with a strong cytochrome P450 protein inhibitor or inducer.
  11. Vaccination with a within 28 days of the first dose of study drug.
  12. Hematopoietic stem cell transplantation within 6 months of first dose of study drug.
  13. Receipt of the following treatment prior to first dose of study drug:

    1. at doses >20 mg/day prednisone equivalent or steroids given with anti-neoplastic intent within 7 days prior to first dose of study drug.
    2. Chemotherapy or radiotherapy within 4 weeks.
    3. Monoclonal antibody within 4 weeks.
    4. therapy within 4 weeks.
    5. Chinese patent medicine with anti-neoplastic intent within 4 weeks.
  14. Not recovered from toxicity of any prior anti-cancer therapy to ≤Grade 1, except for alopecia, ANC, hemoglobin (Hgb), and platelets. For ANC, Hgb and platelets, see inclusion criterion #5.
  15. Prior within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast.
  16. Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, symptomatic inflammatory bowel disease, history of bariatric surgery, or partial or complete bowel obstruction.
  17. Major surgery within 4 weeks prior to first dose of study treatment.
  18. Active fungal, bacterial and/or viral infection requiring systemic therapy.
  19. Known infection with , or serologic status reflecting active or C infection as follows:

    1. Presence of hepatitis B surface antigen (HBsAg) or anti-hepatitis B core antibody (anti-HBc). Participants with presence of anti-HBc, but absence of HBsAg, were eligible if hepatitis B virus (HBV) DNA was \<500 international units (IU)/mL, anti-viral therapy started before the first dose of study treatment, and if they were willing to undergo monthly monitoring for HBV reactivation.
    2. Presence of virus (HCV) antibody. Participants with presence of HCV antibody were eligible if HCV RNA was undetectable (\<15 IU/mL).
  20. Pregnant or lactating women.
  21. Underlying medical conditions that, in the investigator's opinion, would have rendered the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events.
  22. Concurrent participation in another therapeutic clinical trial.

Note: Other protocol defined Inclusion/Exclusion criteria may have applied.

Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    R/R Non-GCB DLBCL

    Participants with non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance.

    Drug: Zanubrutinib · Drug: Rituximab

  • Experimental
    R/R FL or MZL

    Participants with R/R FL or MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance.

    Drug: Zanubrutinib · Drug: Rituximab

Interventions

  • Administered zanubrutinib 160 mg orally (PO) BID continuously

    Also known as: BGB-3111

  • Administered rituximab 375 mg/m\^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) As Measured By The Investigator

    The percentage of participants whose best overall response met partial response (PR) or complete response (CR) criteria among all participants. The 95% confidence interval (CI) was calculated with the Clopper-Pearson method.

    Time frame: Up to approximately 2.5 years

Secondary outcomes

  1. Duration Of Response (DOR) As Determined By Investigator

    The DOR was defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.

    Time frame: Up to approximately 2.5 years

  2. DOR: Event-free Rate

    The DOR was defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. The event-free rate was estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.

    Time frame: Up to approximately 2.5 years

  3. Progression-free Survival (PFS) As Determined By Investigator

    The PFS was defined as time from first dose of study treatment until first documentation of progression, assessed per the Lugano Classification, or death, whichever occurred first. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.

    Time frame: Up to approximately 2.5 years

  4. PFS: Event-free Rate

    The PFS was defined as time from first dose of study treatment until first documentation of progression, assessed per the Lugano Classification, or death, whichever occurred first. The event-free rate was estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.

    Time frame: Up to approximately 2.5 years

  5. Overall Survival (OS)

    The OS was defined as the time from the date of first dose of study treatment to the date of death due to any cause. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

    Time frame: Up to approximately 2.5 years

  6. OS: Survival Rate

    The OS was defined as the time from the date of first dose of study treatment to the date of death due to any cause. Survival rates were estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.

    Time frame: Up to approximately 2.5 years

  7. Time To Response (TTR) As Determined By The Investigator

    The TTR was defined as the time from the date of the first dose of study treatment to the date of the first qualifying response (partial response or better).

    Time frame: Up to approximately 2.5 years

  8. Median TTR

    The TTR was defined as the time from the date of the first dose of study treatment to the date of the first qualifying response (partial response or better).

    Time frame: Up to approximately 2.5 years

  9. Complete Response Rate As Determined By The Investigator

    The percentage of participants whose best overall response met complete response or complete metabolic response criteria among all participants are reported. The 95% CI was calculated with Clopper-Pearson method.

    Time frame: Up to approximately 2.5 years

  10. Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) And Serious TEAEs

    A treatment-emergent adverse event was defined as an adverse event with an onset or worsening (if present pretreatment) starting on or after the first dose of study drug up to 30 days after discontinuation of zanubrutinib or 90 days after discontinuation of rituximab, whichever occurred later; or initiation of new anticancer therapy if it occurred prior to the other 2 dates. Worsening of a treatment-emergent adverse event to Grade 5 beyond Day 30 after the last dose of zanubrutinib or Day 90 after the last dose rituximab was also considered a treatment-emergent adverse event if the event occurred prior to initiation of new anticancer therapy.

    Time frame: Up to approximately 2.5 years

07

Results

Posted Oct 28, 2021

Participant flow

This study was conducted at 4 study centers in China, all of which enrolled participants. The first enrolled participants received their first dose on 04 January 2018, and the last participant enrolled received their first dose on 20 December 2018. A total of 41 participants with non-Hodgkin lymphoma (NHL) were enrolled into the study, and all received ≥1 dose of study treatment.

Participant flow — Overall Study
MilestoneRelapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma
Started20165
Received at least 1 dose of study drug20165
Completed000
Not completed20165
Withdrew: Death1310
Withdrew: Withdrawal by subject210
Withdrew: Study terminated by the sponsor5145

Outcome measures

PrimaryOverall Response Rate (ORR) As Measured By The Investigator

The percentage of participants whose best overall response met partial response (PR) or complete response (CR) criteria among all participants. The 95% confidence interval (CI) was calculated with the Clopper-Pearson method.

Time frame:
Up to approximately 2.5 years
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR) As Measured By The Investigator
Percentage of ParticipantsRelapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma
Overall Response Rate (ORR) As Measured By The Investigator35 (15.4 to 59.2)56.3 (29.9 to 80.2)60.0 (14.7 to 94.7)
SecondaryDuration Of Response (DOR) As Determined By Investigator

The DOR was defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.

Time frame:
Up to approximately 2.5 years
Reported as:
Median · Months
Duration Of Response (DOR) As Determined By Investigator
MonthsRelapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma
Duration Of Response (DOR) As Determined By Investigator8.79 (0.72 to NA)NA (5.45 to NA)22.18 (8.31 to NA)
SecondaryDOR: Event-free Rate

The DOR was defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. The event-free rate was estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.

Time frame:
Up to approximately 2.5 years
Reported as:
Number · Percentage of Participants
DOR: Event-free Rate
Percentage of ParticipantsRelapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma
6 months50.0 (11.1 to 80.4)88.9 (43.3 to 98.4)100.0 (NA to NA)
9 months50.0 (11.1 to 80.4)77.8 (36.5 to 93.9)66.7 (5.4 to 94.5)
12 months50.0 (11.1 to 80.4)64.8 (25.3 to 87.2)66.7 (5.4 to 94.5)
15 months33.3 (4.6 to 67.6)51.9 (16.4 to 78.8)66.7 (5.4 to 94.5)
18 months33.3 (4.6 to 67.6)51.9 (16.4 to 78.8)66.7 (5.4 to 94.5)
24 monthsNA (NA to NA)NA (NA to NA)33.3 (0.9 to 77.4)
SecondaryProgression-free Survival (PFS) As Determined By Investigator

The PFS was defined as time from first dose of study treatment until first documentation of progression, assessed per the Lugano Classification, or death, whichever occurred first. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.

Time frame:
Up to approximately 2.5 years
Reported as:
Median · Months
Progression-free Survival (PFS) As Determined By Investigator
MonthsRelapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma
Progression-free Survival (PFS) As Determined By Investigator3.38 (2.69 to 5.49)11.10 (5.49 to NA)24.87 (11.01 to NA)
SecondaryPFS: Event-free Rate

The PFS was defined as time from first dose of study treatment until first documentation of progression, assessed per the Lugano Classification, or death, whichever occurred first. The event-free rate was estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.

Time frame:
Up to approximately 2.5 years
Reported as:
Number · Percentage of Participants
PFS: Event-free Rate
Percentage of ParticipantsRelapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma
6 months17.4 (4.3 to 37.7)73.3 (43.3 to 89.1)100.0 (NA to NA)
9 months17.4 (4.3 to 37.7)66.7 (37.5 to 84.6)100.0 (NA to NA)
12 months17.4 (4.3 to 37.7)46.7 (21.2 to 68.7)80.0 (20.4 to 96.9)
15 months17.4 (4.3 to 37.7)46.7 (21.2 to 68.7)60.0 (12.6 to 88.2)
18 months11.6 (2.0 to 30.7)40.0 (16.5 to 62.8)60.0 (12.6 to 88.2)
24 months11.6 (2.0 to 30.7)40.0 (16.5 to 62.8)60.0 (12.6 to 88.2)
SecondaryOverall Survival (OS)

The OS was defined as the time from the date of first dose of study treatment to the date of death due to any cause. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

Time frame:
Up to approximately 2.5 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsRelapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma
Overall Survival (OS)11.20 (5.39 to 24.44)NA (NA to NA)NA (NA to NA)
SecondaryOS: Survival Rate

The OS was defined as the time from the date of first dose of study treatment to the date of death due to any cause. Survival rates were estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.

Time frame:
Up to approximately 2.5 years
Reported as:
Number · Percentage of Participants
OS: Survival Rate
Percentage of ParticipantsRelapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma
6 months72.7 (46.3 to 87.6)93.3 (61.3 to 99.0)100.0 (NA to NA)
9 months55.9 (30.8 to 75.0)93.3 (61.3 to 99.0)100.0 (NA to NA)
12 months44.7 (21.8 to 65.4)93.3 (61.3 to 99.0)100.0 (NA to NA)
15 months33.6 (13.8 to 54.8)93.3 (61.3 to 99.0)100.0 (NA to NA)
18 months33.6 (13.8 to 54.8)93.3 (61.3 to 99.0)100.0 (NA to NA)
24 months33.6 (13.8 to 54.8)93.3 (61.3 to 99.0)100.0 (NA to NA)
SecondaryTime To Response (TTR) As Determined By The Investigator

The TTR was defined as the time from the date of the first dose of study treatment to the date of the first qualifying response (partial response or better).

Time frame:
Up to approximately 2.5 years
Reported as:
Mean · Months
Time To Response (TTR) As Determined By The Investigator
MonthsRelapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma
Time To Response (TTR) As Determined By The Investigator3.56 ± 2.0546.15 ± 3.8673.67 ± 1.631
SecondaryMedian TTR

The TTR was defined as the time from the date of the first dose of study treatment to the date of the first qualifying response (partial response or better).

Time frame:
Up to approximately 2.5 years
Reported as:
Median · Months
Median TTR
MonthsRelapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma
Median TTR2.79 (2.7 to 8.2)5.49 (2.6 to 13.8)2.73 (2.7 to 5.6)
SecondaryComplete Response Rate As Determined By The Investigator

The percentage of participants whose best overall response met complete response or complete metabolic response criteria among all participants are reported. The 95% CI was calculated with Clopper-Pearson method.

Time frame:
Up to approximately 2.5 years
Reported as:
Number · Percentage of Participants
Complete Response Rate As Determined By The Investigator
Percentage of ParticipantsRelapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma
Complete Response Rate As Determined By The Investigator10.0 (1.2 to 31.7)18.8 (4.0 to 45.6)0.0 (0.0 to 52.2)
SecondaryNumber Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) And Serious TEAEs

A treatment-emergent adverse event was defined as an adverse event with an onset or worsening (if present pretreatment) starting on or after the first dose of study drug up to 30 days after discontinuation of zanubrutinib or 90 days after discontinuation of rituximab, whichever occurred later; or initiation of new anticancer therapy if it occurred prior to the other 2 dates. Worsening of a treatment-emergent adverse event to Grade 5 beyond Day 30 after the last dose of zanubrutinib or Day 90 after the last dose rituximab was also considered a treatment-emergent adverse event if the event occurred prior to initiation of new anticancer therapy.

Time frame:
Up to approximately 2.5 years
Reported as:
Count of participants · Participants
Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) And Serious TEAEs
ParticipantsRelapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma
Participants With at Least 1 TEAE20165
Serious TEAEs740

Adverse events

Collected over Day 1 through approximately 2.5 years. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma13/20 (65%)7/20 (35%)19/20 (95%)
Relapsed/Refractory Follicular Lymphoma1/16 (6.3%)4/16 (25%)16/16 (100%)
Relapsed/Refractory Marginal Zone Lymphoma0/5 (0%)0/5 (0%)5/5 (100%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventRelapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma
DyspnoeaRespiratory, thoracic and mediastinal disorders2/200/160/5
Abdominal painGastrointestinal disorders2/200/160/5
LymphangitisInfections and infestations0/201/160/5
PneumoniaInfections and infestations0/201/160/5
Pulmonary mycosisInfections and infestations0/201/160/5
Pleural effusionRespiratory, thoracic and mediastinal disorders1/201/160/5
PyrexiaGeneral disorders0/201/160/5
LymphadenopathyBlood and lymphatic system disorders0/201/160/5
Hepatic function abnormalHepatobiliary disorders0/201/160/5
HypoproteinaemiaMetabolism and nutrition disorders0/201/160/5
Most frequent other events
Showing 10 of 36
Most frequent other events
EventRelapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma
Upper respiratory tract infectionInfections and infestations1/203/164/5
White blood cell count decreasedInvestigations5/205/163/5
Neutrophil count decreasedInvestigations4/204/163/5
Urinary tract infectionInfections and infestations0/202/162/5
AnaemiaBlood and lymphatic system disorders4/203/162/5
PyrexiaGeneral disorders1/203/162/5
AstheniaGeneral disorders0/201/162/5
HaematuriaRenal and urinary disorders0/204/162/5
Abdominal pain upperGastrointestinal disorders5/201/161/5
CoughRespiratory, thoracic and mediastinal disorders0/204/160/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone LymphomaTotal
Mean55.2 ± 15.0047.6 ± 12.3661.2 ± 8.8753.0 ± 13.94
Age, Customized
Age, Customized(Participants)Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone LymphomaTotal
<65 years1415332
≥65 years6129
Sex: Female, Male
Sex: Female, Male(Participants)Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone LymphomaTotal
Female78318
Male138223
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone LymphomaTotal
American Indian or Alaska Native0000
Asian2016541
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Body Mass Index
Body Mass Index(kilogram/m^2)Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone LymphomaTotal
Mean23.43 ± 2.65225.04 ± 5.07924.33 ± 4.81324.17 ± 3.989
Body Surface Area
Body Surface Area(m^2)Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone LymphomaTotal
Mean1.72 ± 0.1131.77 ± 0.2951.69 ± 0.2401.74 ± 0.213
Eastern Cooperative Oncology Group Performance (ECOG)Status
Eastern Cooperative Oncology Group Performance (ECOG)Status(Participants)Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone LymphomaTotal
Grade 01311327
Grade 154211
Grade 22103
Hepatitis B Core Antibody
Hepatitis B Core Antibody(Participants)Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone LymphomaTotal
Positive63211
Negative1413229
Missing0011
08

Study locations

4 sites
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221000, China
  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200092, China
09

References and documents

Publications

  • Qingyuan Zhang, Rong Tao, Zhenyu Li, et al. Zanubrutinib (BGB-3111) in combination with rituximab in patients with relapsed/refractory Non-Hodgkin Lymphoma [EHA-2188].

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Aug 2020, 31 months.

Results were first posted in Oct 2021, 1 year 2 months after primary completion.

Of 113 phase 2 interventional studies under Lymphoma, B-Cell, Marginal Zone, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 110. This study's 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2018
First posted
May 11, 2018
StartActual
Jan 4, 2018
Primary completionActual
Aug 28, 2020
CompletionActual
Aug 28, 2020
Results first posted
Oct 28, 2021
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03520920
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
May 11, 2018
Start date
Jan 4, 2018
Primary completion
Aug 28, 2020
Completion
Aug 28, 2020
Results posted
Oct 28, 2021
Last update
Oct 26, 2024

Study contacts

Study Director
principal investigator · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion